Login to Your Account

Kymab Lands First Kymouse Antibody Deal with Novo

By Cormac Sheridan
Staff Writer

Monday, April 22, 2013
Novo Nordisk A/S is the first taker for Kymab Ltd.'s second-generation transgenic mouse antibody platform Kymouse, providing all-important industry validation for the fledgling technology, as well license fees, development milestones and royalties on eventual product sales.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription